Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42032 | 0.83 | CA1 (0.50) | ENPP2CA1CA2CA12CA7 | |
| SCHEMBL29636771 | 0.83 | CA1 (0.50) | ENPP2CA1CA2CA12CA7 | |
| SCHEMBL6886441 | 0.79 | ATM (0.39) | ENPP2CA1CA2MAPTGAA | |
| SCHEMBL7238518 | 0.78 | ERN1 (0.55) | ENPP2CA1CA2CA12CA7 | |
| SCHEMBL29385414 | 0.78 | TUBB4A (0.59) | ENPP2CA1CA2CA12CA7 | |
| SCHEMBL518510 | 0.78 | TUBB4A (0.59) | ENPP2CA1CA2CA12CA7 | |
| SCHEMBL29952460 | 0.78 | ERN1 (0.55) | ENPP2CA1CA2CA12CA7 | |
| SCHEMBL9935773 | 0.77 | ENPP2 (0.48) | ENPP2CA1CA2CA12CA7 | |
| SCHEMBL3789771 | 0.77 | ALDH1A1 (0.53) | ENPP2CA1CA2CA12CA7 | |
| SCHEMBL645367 | 0.77 | ENPP2 (0.48) | ENPP2CA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622967-A1 | COMPOUNDS THAT INHIBIT PKMYT1 | Exelixis, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | PRAGMA THERAPEUTICS (FR) | 2025-08-14 | — | — | US | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| WO-2025064567-A1 | TRICYCLIC PHENOLS FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | PRAGMA THERAPEUTICS (FR) | 2025-02-25 | — | — | US | disclosed |
| CN-111148744-B | Novel heterocyclic compounds as MGLUR7 modulators | 布拉格玛治疗公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142382-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | TARGEGEN, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005096784-A2 | BENZOTRIAZINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | disclosed |
| US-6835745-B2 | Treating or inhibiting osteoporosis or bone demineralization, inflammatory bowel disease, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometriosis, endometrial cardiovascular disease, Alzheimer's disease | WYETH | 2004-12-28 | — | — | US | disclosed |
| US-20030199570-A1 | Phenyl substituted thiophenes as estrogenic agents | WYETH | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ENPP2 715/4885CA1 2925/4885CA2 426/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | ENPP2 715/4885CA1 2925/4885CA2 426/4885 |
| US-20250257049-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF MGLUR7 | GRM7, GRM1, GRM2 | ENPP2 678/4885CA1 2025/4885CA2 1911/4885 |
| US-20070142328-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | ENPP2 879/4885CA1 140/4885CA2 2291/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | ENPP2 520/4885CA1 4843/4885CA2 1067/4885 |
| US-20070142382-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | ENPP2 879/4885CA1 140/4885CA2 2291/4885 |
| US-12234218-B2 | Heterocyclic compounds as modulators of mGluR7 | GRM7, GRM1, GRM2 | ENPP2 678/4885CA1 2025/4885CA2 1911/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | ENPP2 715/4885CA1 2925/4885CA2 426/4885 |
| US-20030199570-A1 | Phenyl substituted thiophenes as estrogenic agents | ESR2, ESR1, GPER1 | ENPP2 3106/4885CA1 2950/4885CA2 1278/4885 |
| US-20050245524-A1 | Benzotriazine inhibitors of kinases | SRC, CAMK4, CAMK2G | ENPP2 1856/4885CA1 3214/4885CA2 247/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | ENPP2 1745/4885CA1 3767/4885CA2 2818/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | ENPP2 520/4885CA1 4843/4885CA2 1067/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | ENPP2 1840/4885CA1 3990/4885CA2 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.